Comparison of cancer risk estimates based on a variety of risk assessment methodologies.

The EPA guidelines recommend a benchmark dose as a point of departure (PoD) for low-dose cancer risk assessment. Generally the PoD is the lower 95% confidence limit on the dose estimated to produce an extra lifetime cancer risk of 10% (LTD(10)). Due to the relatively narrow range of doses in two-year bioassays and the limited range of statistically significant tumor incidence rates, the estimate of the LTD(10) is constrained to a relatively narrow range of values. Because of this constraint, simple, quick estimates of the LTD(10) can be readily obtained for hundreds of rodent carcinogens from the Carcinogenic Potency Database (CPDB) of Gold et al. Three estimation procedures for LTD(10) are described, using increasing information from the CPDB: (A) based on only the maximum tolerated dose (the highest dose tested); (B) based on the TD(50); and (C) based on the TD(50) and its lower 99% confidence limit. As expected, results indicate overall similarity of the LTD(10) estimates and the value of using additional information. For Method (C) the estimator based on the [[(TD(50))(0.36) x (LoConf)(0.64)]/6.6] is generally similar to the estimator based on the one-hit model or multistage model LTD(10). This simple estimate of the LTD(10) is applicable for both linear and curved dose responses with high or low background tumor rates, and whether the confidence limits on the TD(50) are wide or tight. The EPA guidelines provide for a margin of exposure approach if data are sufficient to support a nonlinear dose-response. The reference dose for cancer for a nonlinear dose-response curve based on a 10,000-fold uncertainty (safety) factor from the LTD(10), i.e., the LTD(10)/10,000, is mathematically equivalent to the value for a linear extrapolation from the LTD(10) to the dose corresponding to a cancer risk of <10(-5) (LTD(10)/10,000). The cancer risk at <10(-5) obtained by using the q(1)(*) from the multistage model, is similar to LTD(10)/10,000. For a nonlinear case, an uncertainty factor of less than 10,000 is likely to be used, which would result in a higher (less stringent) acceptable exposure level.

[1]  B. Ames,et al.  Paracelsus to parascience: the environmental cancer distraction. , 2000, Mutation research.

[2]  J. Wiltse,et al.  US Environmental Protection Agency's revised guidelines for Carcinogen Risk Assessment: incorporating mode of action data. , 1998, Mutation research.

[3]  J. E. Bailey,et al.  Food Quality Protection Act of 1996 , 2003 .

[4]  D. Gaylor,et al.  Quick estimate of the regulatory virtually safe dose based on the maximum tolerated dose for rodent bioassays. , 1995, Regulatory toxicology and pharmacology : RTP.

[5]  F. Roe,et al.  Safety evaluation of toothpaste containing chloroform. III. Long-term study in beagle dogs. , 1979, Journal of environmental pathology and toxicology.

[6]  J J Chen,et al.  Uncertainty in cancer risk estimates. , 1993, Risk analysis : an official publication of the Society for Risk Analysis.

[7]  L. Tuxen,et al.  Integrated risk information system (IRIS) , 1990 .

[8]  R. Bull,et al.  Carcinogenicity of chloroform in drinking water to male Osborne-Mendel rats and female B6C3F1 mice. , 1985, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[9]  B. Ames,et al.  What do animal cancer tests tell us about human cancer risk?: Overview of analyses of the carcinogenic potency database. , 1998, Drug metabolism reviews.

[10]  E. Zeiger,et al.  Handbook of Carcinogenic Potency and Genotoxicity Databases , 1996 .

[11]  A M Jarabek,et al.  The application of dosimetry models to identify key processes and parameters for default dose-response assessment approaches. , 1995, Toxicology letters.

[12]  D. Barnes,et al.  Reference dose (RfD): description and use in health risk assessments. , 1988, Regulatory toxicology and pharmacology : RTP.

[13]  David G. Hoel,et al.  Some Tautologous Aspects of the Comparison of Carcinogenic Potency in Rats and Mice , 1985 .

[14]  D. Gaylor Relationship between the shape of dose-response curves and background tumor rates. , 1992, Regulatory toxicology and pharmacology : RTP.

[15]  A G Renwick The use of an additional safety or uncertainty factor for nature of toxicity in the estimation of acceptable daily intake and tolerable daily intake values. , 1995, Regulatory toxicology and pharmacology : RTP.

[16]  L. Gold,et al.  Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature in 1993 to 1994 and by the National Toxicology Program in 1995 to 1996. , 1999, Environmental health perspectives.

[17]  A semiquantitative method for selection of safety factors in establishing OELs for pharmaceutical compounds , 1995 .

[18]  D W Gaylor,et al.  Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose. , 1998, Regulatory toxicology and pharmacology : RTP.